{"product_id":"proteogenix-obertamig-biosimilar-anti-hlag-mab-research-grade","title":"Obertamig Biosimilar – Anti-HLAG mAb – Research Grade","description":"\u003ch3\u003eIntroduction\u003c\/h3\u003e \u003cp\u003eObertamig Biosimilar – Anti-HLAG mAb is a novel therapeutic antibody targeting the Human Leukocyte Antigen-G (HLA-G) protein. This biosimilar is a recombinant monoclonal antibody (mAb) that has been developed for research purposes. In this article, we will provide a detailed scientific description of the structure, activity, and potential applications of Obertamig Biosimilar – Anti-HLAG mAb.\u003c\/p\u003e \u003ch3\u003eStructure of Obertamig Biosimilar – Anti-HLAG mAb\u003c\/h3\u003e \u003cp\u003eObertamig Biosimilar – Anti-HLAG mAb is a humanized IgG1 monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of the antibody is responsible for binding to the HLA-G protein, while the constant region is responsible for effector functions such as complement activation and antibody-dependent cellular cytotoxicity.\u003c\/p\u003e \u003cp\u003eThe amino acid sequence of Obertamig Biosimilar – Anti-HLAG mAb has been engineered to have a high affinity and specificity for HLA-G. This has been achieved by using a combination of human and murine sequences, resulting in a chimeric antibody with a reduced immunogenicity potential.\u003c\/p\u003e \u003ch3\u003eActivity of Obertamig Biosimilar – Anti-HLAG mAb\u003c\/h3\u003e \u003cp\u003eThe primary mode of action of Obertamig Biosimilar – Anti-HLAG mAb is the binding and neutralization of HLA-G. HLA-G is a non-classical major histocompatibility complex (MHC) class I molecule that is expressed on the surface of various cells, including tumor cells and immune cells. It plays a critical role in immune tolerance and has been implicated in the escape of tumor cells from immune surveillance.\u003c\/p\u003e \u003cp\u003eObertamig Biosimilar – Anti-HLAG mAb binds to HLA-G with high affinity and blocks its interaction with its receptors, including the inhibitory receptors on immune cells. This results in the activation of immune cells and the enhancement of anti-tumor immune responses. Additionally, Obertamig Biosimilar – Anti-HLAG mAb can induce antibody-dependent cellular cytotoxicity, leading to the destruction of HLA-G-expressing tumor cells.\u003c\/p\u003e \u003ch3\u003eApplications of Obertamig Biosimilar – Anti-HLAG mAb\u003c\/h3\u003e \u003cp\u003eObertamig Biosimilar – Anti-HLAG mAb has potential applications in various fields, including cancer research and immunotherapy. Its ability to block the immunosuppressive effects of HLA-G makes it a promising candidate for the treatment of cancer. It can be used alone or in combination with other anti- cancer therapies to enhance their efficacy.\u003c\/p\u003e \u003cp\u003eIn addition to cancer, Obertamig Biosimilar – Anti-HLAG mAb has also shown potential in the treatment of autoimmune diseases. HLA-G has been implicated in the pathogenesis of various autoimmune disorders, and Obertamig Biosimilar – Anti-HLAG mAb can potentially modulate immune responses and ameliorate disease symptoms.\u003c\/p\u003e \u003cp\u003eFurthermore, Obertamig Biosimilar – Anti-HLAG mAb can also be used as a research tool to study the role of HLA-G in immune tolerance and cancer progression. Its high specificity and affinity for HLA-G make it a valuable tool for studying the mechanisms of action of this protein and its potential as a therapeutic target.\u003c\/p\u003e \u003ch3\u003eConclusion\u003c\/h3\u003e \u003cp\u003eIn summary, Obertamig Biosimilar – Anti-HLAG mAb is a novel therapeutic antibody targeting HLA-G. Its unique structure and high specificity for HLA-G make it a promising candidate for the treatment of cancer and autoimmune diseases. It can also serve as a valuable research tool for studying the role of HLA-G in various diseases. Further studies and clinical trials are needed to fully explore the potential of Obertamig Biosimilar – Anti-HLAG mAb as a therapeutic agent.\u003c\/p\u003e\u003cp\u003eProteoGenix catalogue number PX-TA1980. For research use only.\u003c\/p\u003e\u003cp\u003eTarget: Obertamig Biosimilar – Anti-HLAG mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: 0.01M PBS, pH 7.4; Applications: WB, ELISA.\u003c\/p\u003e\u003cp\u003eAvailable configurations: 50ug, 100ug, 1mg.\u003c\/p\u003e\u003cp\u003e\u003ca href=\"https:\/\/www.proteogenix.science\/wp-content\/uploads\/documents\/Datasheets\/PX-TA1980.pdf\"\u003eDownload the manufacturer datasheet\u003c\/a\u003e\u003c\/p\u003e","brand":"ProteoGenix","offers":[{"title":"50ug","offer_id":57357660389716,"sku":"ABM134082-1","price":124.0,"currency_code":"GBP","in_stock":true},{"title":"100ug","offer_id":57357660422484,"sku":"ABM134082-2","price":167.2,"currency_code":"GBP","in_stock":true},{"title":"1mg","offer_id":57357660455252,"sku":"ABM134082-3","price":327.2,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1040\/1782\/2036\/files\/sds-validation-2-obertamig-biosimilar-anti-hlag-mab-research-grade_c74c4ed2-d8c2-41ee-84f8-ad445be915b3.jpg?v=1790890881","url":"https:\/\/www.abmium.com\/es\/products\/proteogenix-obertamig-biosimilar-anti-hlag-mab-research-grade","provider":"ABMIUM","version":"1.0","type":"link"}